Veracyte, Inc. $VCYT Stock Bought by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. raised its holdings in Veracyte, Inc. (NASDAQ:VCYT) by 2.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 784,483 shares of the biotechnology company’s stock after buying an additional 15,534 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.98% of Veracyte worth $36,118,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Veracyte during the third quarter valued at $189,000. Profund Advisors LLC increased its position in shares of Veracyte by 53.4% during the third quarter. Profund Advisors LLC now owns 37,882 shares of the biotechnology company’s stock worth $1,744,000 after acquiring an additional 13,188 shares in the last quarter. Summit Global Investments lifted its position in shares of Veracyte by 318.0% in the third quarter. Summit Global Investments now owns 20,017 shares of the biotechnology company’s stock worth $922,000 after purchasing an additional 15,228 shares in the last quarter. State of Wyoming increased its position in shares of Veracyte by 56.0% in the third quarter. State of Wyoming now owns 9,661 shares of the biotechnology company’s stock valued at $445,000 after acquiring an additional 3,469 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Veracyte by 70.2% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 20,850 shares of the biotechnology company’s stock worth $960,000 after purchasing an additional 8,600 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Piper Sandler cut their target price on Veracyte from $66.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Needham & Company LLC reissued a “buy” rating on shares of Veracyte in a research note on Tuesday, September 15th. Canaccord Genuity Group reduced their price objective on Veracyte from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday, August 3rd. Morgan Stanley reduced their price objective on shares of Veracyte from $47.00 to $44.00 and set an “underweight” rating for the company in a report on Tuesday, August 4th. Finally, Stephens cut their price target on shares of Veracyte from $68.00 to $55.00 and set an “overweight” rating on the stock in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $55.78.

Insiders Place Their Bets

In other news, insider John Leite sold 4,015 shares of the firm’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $40.00, for a total value of $160,600.00. Following the completion of the sale, the insider owned 124,329 shares in the company, valued at approximately $4,973,160. This trade represents a 3.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karin Eastham sold 14,850 shares of the firm’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $50.00, for a total value of $742,500.00. Following the sale, the director directly owned 10,247 shares of the company’s stock, valued at $512,350. This represents a 59.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 62,609 shares of company stock worth $2,858,904. 1.60% of the stock is currently owned by company insiders.

Veracyte Trading Up 4.4%

Veracyte stock opened at $52.52 on Thursday. The firm has a market cap of $4.22 billion, a P/E ratio of 37.25 and a beta of 1.98. Veracyte, Inc. has a 1-year low of $29.45 and a 1-year high of $60.91. The firm has a 50-day moving average of $44.90 and a 200-day moving average of $43.04.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.10. The business had revenue of $151.75 million during the quarter, compared to the consensus estimate of $147.13 million. Veracyte had a return on equity of 9.26% and a net margin of 20.37%. The firm’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.51 earnings per share. Research analysts forecast that Veracyte, Inc. will post 1.32 earnings per share for the current fiscal year.

Veracyte News Summary

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Third-quarter revenue rose 15% year over year to $151.8 million, beating the $147.1 million consensus estimate. Adjusted EPS of $0.51 also topped estimates of $0.41–$0.44, though it was unchanged from a year earlier. Veracyte Announces Third Quarter 2026 Financial Results
• Positive Sentiment: The company authorized a $100 million share repurchase program. Buybacks can signal management confidence and support per-share results by reducing the number of shares outstanding. Veracyte authorizes a Buyback Plan
• Neutral Sentiment: Analysts’ average price target was reported at $55.78. The target suggests some potential upside from the $52.52 opening price cited in the background, but it is an estimate rather than a guarantee. Veracyte Stock Has Average Price Target of $55.78

Veracyte Profile

Veracyte, Inc is a diagnostics company that develops genomic tests to help physicians diagnose cancer, assess disease risk and guide treatment decisions. Its tests are designed to provide additional molecular information from patient samples, often helping reduce uncertainty and support more personalized care.

The company’s portfolio includes Afirma tests for thyroid nodules, Decipher tests for prostate cancer, Percepta tests for lung cancer and Envisio tests for breast cancer. Veracyte also develops and commercializes additional genomic assays intended for use across various cancer types and clinical settings.

Founded in 2008 and headquartered in South San Francisco, California, Veracyte primarily serves the U.S.